Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1995-9-5
pubmed:abstractText
Granulocyte infiltration is a prominent feature of human psoriasis. Psoriatic lesional skin contains abnormally high amounts of immunoreactive leukotriene B4 (LTB4), a potent granulocyte chemotaxin in vivo and in vitro. SC-53228 [(+)-(S)-7-(3-}2-(cyclopropylmethyl)-3-methoxy-4- [(methylamino)carbonyl]phenoxy}propoxy}-3,4-dihydro-8-propyl-2H-1- benzopyran-2-propanoic acid], a second-generation LTB4 receptor antagonist, was tested topically and orally in phorbol ester-induced dermal inflammation in three species. Skin inflammation was induced by topical application of phorbol-12-myristate-13-acetate-(PMA/TPA) and assessed by ear thickness, levels of the neutrophil marker enzyme myeloperoxidase (MPO) and histological examination. In mice, SC-53228 inhibited inflammation with a topical ED50 value of 200 +/- 18 micrograms. When applied to guinea pigs, SC-53228 (100 micrograms) inhibited the MPO increase by 86%, while 1000 micrograms abrogated inflammation in rhesus macaques with no plasma accumulation of the drug. A 1% gel formulation was also efficacious in guinea pig PMA-induced epidermal inflammation. Furthermore, single oral dose administration to mice was efficacious (ED50 < 2.5 mg/kg) as was multidose administration to rhesus macaques. PMA-induced skin inflammation possesses some of the attributes of human psoriasis and an agent such as SC-53228 may have utility in the medical management of this condition.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0360-3997
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
333-46
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:7628862-Administration, Cutaneous, pubmed-meshheading:7628862-Administration, Oral, pubmed-meshheading:7628862-Animals, pubmed-meshheading:7628862-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:7628862-Benzamides, pubmed-meshheading:7628862-Benzopyrans, pubmed-meshheading:7628862-Disease Models, Animal, pubmed-meshheading:7628862-Drug Eruptions, pubmed-meshheading:7628862-Drug Evaluation, Preclinical, pubmed-meshheading:7628862-Ear, External, pubmed-meshheading:7628862-Edema, pubmed-meshheading:7628862-Female, pubmed-meshheading:7628862-Gels, pubmed-meshheading:7628862-Guinea Pigs, pubmed-meshheading:7628862-Humans, pubmed-meshheading:7628862-Male, pubmed-meshheading:7628862-Mice, pubmed-meshheading:7628862-Peroxidase, pubmed-meshheading:7628862-Psoriasis, pubmed-meshheading:7628862-Receptors, Leukotriene B4, pubmed-meshheading:7628862-Tetradecanoylphorbol Acetate
pubmed:year
1995
pubmed:articleTitle
Dermal inflammation in primates, mice, and guinea pigs: attenuation by second-generation leukotriene B4 receptor antagonist, SC-53228.
pubmed:affiliation
Department of Inflammatory Diseases Research, Searle Research and Development, Skokie, Illinois 60077, USA.
pubmed:publicationType
Journal Article, Comparative Study